EP Patent

EP4046989A1 — Selective histone deacetylase inhibitors for the treatment of human disease

Assigned to Shuttle Pharmaceuticals Inc · Expires 2022-08-24 · 4y expired

What this patent protects

Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.

USPTO Abstract

Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.

Drugs covered by this patent

Patent Metadata

Patent number
EP4046989A1
Jurisdiction
EP
Classification
—
Expires
2022-08-24
Drug substance claim
No
Drug product claim
No
Assignee
Shuttle Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.